TriSalus Life Sciences (TLSI) Cash from Operations (2021 - 2026)
TriSalus Life Sciences has reported Cash from Operations over the past 5 years, most recently at 6480000.0 for Q1 2026.
- For Q1 2026, Cash from Operations fell 44.03% year-over-year to 6480000.0; the TTM value through Mar 2026 reached 19993000.0, up 42.01%, while the annual FY2025 figure was 18012000.0, 55.9% up from the prior year.
- Cash from Operations for Q1 2026 was 6480000.0 at TriSalus Life Sciences, down from 2484000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 425954.0 in Q1 2022 and troughed at 22880298.0 in Q3 2022.
- A 5-year average of 8719176.47 and a median of 8310000.0 in 2022 define the central range for Cash from Operations.
- Biggest five-year swings in Cash from Operations: crashed 2365.76% in 2023 and later surged 65.81% in 2025.
- Year by year, Cash from Operations stood at 8310000.0 in 2022, then dropped by 10.43% to 9177000.0 in 2023, then skyrocketed by 37.81% to 5707000.0 in 2024, then skyrocketed by 56.47% to 2484000.0 in 2025, then crashed by 160.87% to 6480000.0 in 2026.
- Business Quant data shows Cash from Operations for TLSI at 6480000.0 in Q1 2026, 2484000.0 in Q4 2025, and 3709000.0 in Q3 2025.